Anti-SUMO-2 + SUMO-3 Antibody [SM23/496] - BSA and Azide free (A253165)

Anti-SUMO-2 + SUMO-3 Antibody [SM23/496] - BSA and Azide free

Mouse monoclonal [SM23/496] antibody to SUMO-2 + SUMO-3.

This antibody reacts with both SUMO-2 and SUMO-3. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimers disease.

Flow Cytometry, IF, WB, IHC-P

Flow Cytometry: 1-2 µg/million cells, IF: 1-2 µg/ml, WB: 1-2 µg/ml, IHC-P: 1-2 µg/ml

Human

Recombinant human SUMO2 protein.

Mouse

Monoclonal

SM23/496

kappa

Protein A/G chromatography.

1 mg/ml

11-13 kDa

Liquid

Supplied in 10mM Phosphate Buffered Saline; without Sodium Azide and carrier free.

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

This monoclonal antibody is also available in a different formulation with BSA and Sodium Azide - Anti-SUMO-2 + SUMO-3 Antibody [SM23/496] (A249985).